ArticleFrontiers in immunology2026
Stemness signature RBBP7 reprograms the immune microenvironment to inform a prognostic model in esophageal carcinoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Esophageal carcinoma has high mortality and poor prognosis. Current multimodal therapies remain limited by scarce actionable targets and suboptimal systemic efficacy. Tumor stemness programs sustain invasive, therapy-resistant cells and may offer new opportunities for precision stratification and treatment. Methods: The present study has demonstrated the multifaceted roles of stemness genes in esophageal cancer through integrated multi-omics research. Firstly, the analysis of bulk RNA-seq revealed dysregulation of stemness genes in cancer. Utilizing the high-dimensional WGCNA approach in the context of single cell RNA-seq, we have successfully identified modules that are associated with tumor stemness. Subsequently, Cox regression and LASSO analysis were employed to identify prognostic genes and construct a predictive model. CellChat and functional enrichment studies explored crosstalk between model genes and the microenvironment, while multiple experiments validated the efficacy of these model genes. Results: Through multimodal analysis, stemness exhibits significant differences between esophageal cancer and adjacent normal tissue. By integrating multiple algorithms, we constructed a stemness gene prognostic model. This model accurately predicts prognosis and drug response, with its 1-, 2-, and 3-year survival predictions outperforming TNM staging. The model gene RBBP7 emerges as the most influential prognostic factor. Its overexpression mediates heightened tumor cell stemness and correlated with T follicular helper cells infiltration, thereby reshaping the tumor microenvironment. Conclusion: The stemness gene model has been demonstrated to possess the capacity to accurately predict the prognosis of patients diagnosed with esophageal cancer. It is noteworthy that the model gene RBBP7 has been identified as a promising therapeutic target for addressing the issue of stemness in esophageal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.